4.6 Article

Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume 151, Issue 2, Pages 152-158

Publisher

WILEY
DOI: 10.1111/j.1365-2141.2010.08339.x

Keywords

chronic lymphocytic leukaemia; high risk families; monoclonal B-cell lymphocytosis; flow cytometry

Categories

Funding

  1. National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  2. National Cancer Institute [CA118444, CA116237, CA137941, N01-PC-35141]
  3. Leukemia and Lymphoma Society [61006]
  4. Veterans Affairs Research Service
  5. National Institutes of Health [AI-51445]

Ask authors/readers for more resources

P>Monoclonal B-cell lymphocytosis (MBL) is an asymptomatic haematological condition characterized by low absolute levels of B-cell clones with a surface immunophenotype similar to that of chronic lymphocytic leukaemia (CLL). In the general population, MBL increases with age with a prevalence of 5-9% in individuals over age 60 years. It has been reported to be higher among first-degree relatives from CLL families. We report results of multi-parameter flow cytometry among 505 first-degree relatives with no personal history of lymphoproliferative disease from 140 families having at least two cases of CLL. Seventeen percent of relatives had MBL. Age was the most important determinant where the probability for developing MBL by age 90 years was 61%. MBL clustered in certain families but clustering was independent of the number of known CLL cases in a family. As is the case with CLL, males had a significantly higher risk for MBL than did females (P = 0 center dot 04). MBL patients had significantly higher mean absolute lymphocyte counts (2 center dot 4 x 109/l) and B-cell counts (0 center dot 53 x 109/l) than those with a normal B-cell immuno-phenotype. Our findings show that MBL occurs at a very high rate in high risk CLL families. Both the age and gender distribution of MBL are parallel to CLL, implying a shared inherited risk.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Hematology

Utilization of real-world data in assessing treatment effectiveness for diffuse large B-cell lymphoma

Grzegorz Nowakowski, Matthew J. Maurer, James R. Cerhan, Debarshi Dey, Laurie H. Sehn

Summary: Comparative effectiveness studies using real-world data can provide complementary evidence on treatment effectiveness. By balancing baseline covariates using propensity score methods, closely matched patient-level cohorts can be generated for robust comparative analyses.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Oncology

Physical activity and the risk of non-Hodgkin lymphoma subtypes: A pooled analysis

Terry Boyle, Geffen Kleinstern, Paige M. Bracci, James R. Cerhan, Yolanda Benavente, Delphine Casabonne, Brian C-H Chiu, Thomas M. Habermann, Elizabeth A. Holly, Mark Liebow, Aaron Norman, Ora Paltiel, Dennis Robinson, Nathaniel Rothman, Rania Abu Seir, Susan L. Slager, Paul J. Villeneuve, Sophia S. Wang, Dennis D. Weisenburger, John J. Spinelli

Summary: This study, which pooled data from nine case-control studies, found that moderate-to-vigorous intensity physical activity can reduce the risk of non-Hodgkin lymphoma.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

Genetic ancestry, differential gene expression, and survival in pediatric B-cell acute lymphoblastic leukemia

Freddy A. Barragan, Lauren J. Mills, Andrew R. Raduski, Erin L. Marcotte, Kelsey E. Grinde, Logan G. Spector, Lindsay A. Williams

Summary: Black children have lower incidence yet worse survival in B-cell acute lymphoblastic leukemia (B-ALL). Genetic ancestry and differentially expressed genes associated with ancestry play a role in death risk. The impact of reported race/ethnicity on death risk varies after adjusting for genetic ancestry genes. Other factors also contribute to B-ALL survival.

CANCER MEDICINE (2023)

Article Economics

Breathing new life into death certificates: Extracting handwritten cause of death in the LIFE-M project *

Martha J. Bailey, Susan H. Leonard, Joseph Price, Evan Roberts, Logan Spector, Mengying Zhang

Summary: This paper describes the digitization of almost 185,000 causes of death for Ohio by combining handwriting recognition, data cleaning algorithms, and semi-automated classification of causes. The methods used in this research can be applied to other collections of handwritten data.

EXPLORATIONS IN ECONOMIC HISTORY (2023)

Article Oncology

Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection

Kurt S. Bantilan, Neil E. Kay, Sameer A. Parikh, Kari G. Rabe, Timothy G. Call, Jose F. Leis, Wei Ding, Susan L. Slager, Jacob D. Soumerai, Lindsey E. Roeker, Anthony Mato, Andrew D. Zelenetz

Summary: We aimed to develop a prognostic model to determine who would benefit from first-line chemoimmunotherapy (CIT) vs targeted therapy in chronic lymphocytic leukemia (CLL). Our study found that time from diagnosis to second treatment (TT2T) was a better predictor of overall survival (OS) than time from diagnosis to first treatment (TT1T) in CLL. We developed a risk score model consisting of three predictors (unmutated IGHV, beta(2)-microglobulin >297 nmol/L, and Rai stage I-IV) that was prognostic for TT2T and OS. TT2T shows potential as a surrogate for OS in CLL, but further validation is needed.

LEUKEMIA & LYMPHOMA (2023)

Article Medicine, General & Internal

Evaluation of the Association Between Congenital Cytomegalovirus Infection and Pediatric Acute Lymphoblastic Leukemia

Jennifer M. Geris, Mark R. Schleiss, Anthony J. Hooten, Erica Langer, Nelmary Hernandez-Alvarado, Michelle A. Roesler, Jeannette Sample, Lindsay A. Williams, David S. Dickens, Rajen J. Mody, Yaddanapudi Ravindranath, Kate L. Gowans, Matthew G. Pridgeon, Logan G. Spector, Heather H. Nelson

Summary: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer and a leading cause of death in children. Congenital cytomegalovirus (cCMV) has been identified as a potential risk factor for ALL. This study compared the prevalence of cCMV infection between ALL cases and matched controls, and found that cCMV was associated with increased risk of hyperdiploid ALL.

JAMA NETWORK OPEN (2023)

Article Hematology

Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia

Emelie Curovic Rotbain, Cristine Allmer, Klaus Rostgaard, Michael Asger Andersen, Noomi Vainer, Caspar da Cunha-Bang, Sameer A. Parikh, Kari G. Rabe, Henrik Hjalgrim, Henrik Frederiksen, Susan L. Slager, Carsten Utoft Niemann

Summary: Age-related comorbid conditions, such as type 2 diabetes, are common in patients with chronic lymphocytic leukemia (CLL). This study analyzed two separate cohorts to assess the impact of type 2 diabetes on CLL patient outcomes. The results showed that CLL patients with type 2 diabetes had shorter overall survival, were less likely to receive treatment, and had an increased risk of death due to infections. These findings highlight the need for additional interventions and research to address the treatment needs of CLL patients with co-occurring type 2 diabetes.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Procedure-Specific Center Volume and Mortality After Infantile Congenital Heart Surgery

Rachel Zmora, Logan Spector, John Bass, Amanda Thomas, Jessica Knight, Kamakshi Lakshminarayan, James St Louis, Lazaros Kochilas

Summary: The study found that procedure-specific center volume is inversely associated with early postoperative mortality for infantile congenital heart surgery (CHS) but has no measurable effect on later mortality.

ANNALS OF THORACIC SURGERY (2023)

Letter Oncology

Relationship among three common hematological premalignant conditions

Nicholas J. Boddicker, Sameer A. Parikh, Aaron D. Norman, Kari G. Rabe, Rosalie Griffin, Timothy G. Call, Dennis P. Robinson, Janet E. Olson, Angela Dispenzieri, Vincent Rajkumar, Shaji Kumar, Neil E. Kay, Curtis A. Hanson, James R. Cerhan, David Murray, Esteban Braggio, Tait D. Shanafelt, Celine M. Vachon, Susan L. Slager

LEUKEMIA (2023)

Article Oncology

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era

Cristina Correia, Matthew J. J. Maurer, Samantha J. J. McDonough, Paula A. A. Schneider, Paige E. E. Ross, Anne J. J. Novak, Andrew L. L. Feldman, James R. R. Cerhan, Susan L. L. Slager, Thomas E. E. Witzig, Bruce W. W. Eckloff, Hu Li, Grzegorz S. S. Nowakowski, Scott H. H. Kaufmann

Summary: The identification of follicular lymphoma (FL) patients with low disease burden but high risk for early progression is unclear. In a study on newly diagnosed FLs, BCL2 mutations with high variant allele frequency (VAF) were found to be associated with increased transformation risk and shorter event-free survival. However, other sequenced genes did not contribute significantly to the prognostic value of the panel. Nonsynonymous BCL2 mutations with VAF = 20% were consistently associated with decreased event-free survival and overall survival.

BLOOD CANCER JOURNAL (2023)

Article Hematology

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL

Rosalie Griffin, Julia E. Wiedmeier-Nutor, Sameer A. Parikh, Chantal E. McCabe, Daniel R. O'Brien, Nicholas J. Boddicker, Geffen Kleinstern, Kari G. Rabe, Laura Bruins, Sochilt Brown, Cecilia Bonolo de Campos, Wei Ding, Jose F. Leis, Paul J. Hampel, Timothy G. Call, Daniel L. Van Dyke, Neil E. Kay, James R. Cerhan, Huihuang Yan, Susan L. Slager, Esteban Braggio

Summary: TP53 aberrations are important in CLL and HCMBL, and multi-hit TP53 state is associated with increased risk of requiring therapy and death. Both TP53 mutations and del(17p) provide important prognostic information that should be measured in HCMBL and CLL.

BLOOD ADVANCES (2023)

Letter Hematology

Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment

Samuel R. Kosydar, Sameer A. Parikh, Scott C. Lester, Kari G. Rabe, Wei Ding, Jessica F. Burlile, Saad S. Kenderian, Yucai Wang, Eli Muchtar, Amber B. Koehler, Susan M. Schwager, Susan L. Slager, Neil E. Kay, Timothy G. Call, William G. Breen, Paul J. Hampel

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Environmental Sciences

Modeling historic neighborhood deprivation and non-Hodgkin lymphoma risk

Joseph Boyle, Mary H. Ward, James R. Cerhan, Nathaniel Rothman, David C. Wheeler

Summary: Many studies have found associations between neighborhood deprivation and disease, emphasizing the importance of social determinants of health. However, when studying diseases with long latency periods such as cancers, considering the timing of exposures for deprivation becomes more important.

ENVIRONMENTAL RESEARCH (2023)

Article Oncology

Nonchromosomal birth defects and risk of childhood acute leukemia: An assessment in 15?000 leukemia cases and 46?000 controls from the Childhood Cancer and Leukemia International Consortium

Philip J. Lupo, Tiffany M. Chambers, Beth A. Mueller, Jacqueline Clavel, John D. Dockerty, David R. Doody, Friederike Erdmann, Sameera Ezzat, Tommaso Filippini, Johnni Hansen, Julia E. Heck, Claire Infante-Rivard, Alice Y. Kang, Corrado Magnani, Carlotta Malagoli, Catherine Metayer, Helen D. Bailey, Ana M. Mora, Evangelia Ntzani, Eleni Th Petridou, Maria S. Pombo-de-Oliveira, Wafaa M. Rashed, Eve Roman, Joachim Schuz, Catharina Wesseling, Logan G. Spector, Michael E. Scheurer

Summary: The study explores the associations between nonchromosomal birth defects and childhood leukemia using data from the Childhood Cancer and Leukemia International Consortium. The results suggest possible novel genetic and environmental factors associated with birth defects that may also increase leukemia susceptibility.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report

Cindy Im, Noha Sharafeldin, Yan Yuan, Zhaoming Wang, Yadav Sapkota, Zhanni Lu, Logan G. Spector, Rebecca M. Howell, Michael A. Arnold, Melissa M. Hudson, Kirsten K. Ness, Leslie L. Robison, Smita Bhatia, Gregory T. Armstrong, Joseph P. Neglia, Yutaka Yasui, Lucie M. Turcotte

Summary: This study evaluated SMNs among long-term childhood cancer survivors of European and African genetic ancestry, finding that a polygenic risk score (PRS) could significantly impact SMN risk in survivors who did not receive radiation therapy and were treated with specific chemotherapies.

JOURNAL OF CLINICAL ONCOLOGY (2023)

No Data Available